PMID- 20467418
OWN - NLM
STAT- MEDLINE
DCOM- 20110504
LR  - 20181201
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 19
IP  - 1
DP  - 2011 Jan
TI  - Rosiglitazone improves glucose metabolism in obese adolescents with impaired 
      glucose tolerance: a pilot study.
PG  - 94-9
LID - 10.1038/oby.2010.109 [doi]
AB  - Impaired glucose tolerance (IGT) is a prediabetic state fueling the rising 
      prevalence of type 2 diabetes mellitus (T2DM) in adolescents with marked obesity. 
      Given the importance of insulin resistance, the poor beta-cell compensation and the 
      altered fat partitioning as underlying defects associated with this condition, it 
      is crucial to determine the extent to which these underlying abnormalities can be 
      reversed in obese adolescents. We tested, in a pilot study, whether rosiglitazone 
      (ROSI) restores normal glucose tolerance (NGT) in obese adolescents with IGT by 
      improving insulin sensitivity and beta-cell function. In a small randomized, 
      double-blind, placebo (PLA)-controlled study, lasting 4 months, 21 obese 
      adolescents with IGT received either ROSI (8 mg daily) (n = 12, 5M/7F, BMI 
      z-score 2.44 +/- 0.11) or PLA (n = 9, 4M/5F, BMI z-score 2.41 +/- 0.09). Before and 
      after treatment, all subjects underwent oral glucose tolerance test (OGTT), 
      hyperinsulinemic-euglycemic clamp, magnetic resonance imaging, and (1)H NMR 
      assessment. After ROSI treatment, 58% of the subjects converted to NGT compared 
      to 44% in the PLA group (P = 0.528). Restoration of NGT was associated with a 
      significant increase in insulin sensitivity (P < 0.04) and a doubling in the 
      disposition index (DI) (P < 0.04), whereas in the PLA group, these changes were 
      not significant. The short-term use of ROSI appears to be safe in obese 
      adolescents with IGT. ROSI restores NGT by increasing peripheral insulin 
      sensitivity and beta-cell function, two principal pathophysiological abnormalities 
      of IGT.
FAU - Cali, Anna M G
AU  - Cali AM
AD  - Department of Pediatrics, Yale University School of Medicine, New Haven, 
      Connecticut, USA.
FAU - Pierpont, Bridget M
AU  - Pierpont BM
FAU - Taksali, Sara E
AU  - Taksali SE
FAU - Allen, Karin
AU  - Allen K
FAU - Shaw, Melissa M
AU  - Shaw MM
FAU - Savoye, Mary
AU  - Savoye M
FAU - Caprio, Sonia
AU  - Caprio S
LA  - eng
GR  - K24-HD01464/HD/NICHD NIH HHS/United States
GR  - R01-EB006494/EB/NIBIB NIH HHS/United States
GR  - R01-HD40787/HD/NICHD NIH HHS/United States
GR  - UL1 RR0249139/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20100513
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Placebos)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adolescent
MH  - Body Composition/drug effects/physiology
MH  - Body Weight/drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Glucose/*metabolism
MH  - Glucose Intolerance/complications/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/pharmacology/therapeutic use
MH  - Male
MH  - Obesity/complications/*drug therapy/metabolism
MH  - Patient Compliance
MH  - Pilot Projects
MH  - Placebos
MH  - Rosiglitazone
MH  - Thiazolidinediones/adverse effects/pharmacology/*therapeutic use
MH  - Treatment Outcome
EDAT- 2010/05/15 06:00
MHDA- 2011/05/05 06:00
CRDT- 2010/05/15 06:00
PHST- 2010/05/15 06:00 [entrez]
PHST- 2010/05/15 06:00 [pubmed]
PHST- 2011/05/05 06:00 [medline]
AID - oby2010109 [pii]
AID - 10.1038/oby.2010.109 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2011 Jan;19(1):94-9. doi: 10.1038/oby.2010.109. Epub 
      2010 May 13.